This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.
Roche Holding's (RHHBY) Accu-Chek SmartGuide Receives CE Mark
by Zacks Equity Research
Roche Holding (RHHBY) announces the receipt of CE Mark for its Accu-Chek SmartGuide CGM solution which is intended toward providing better diabetes management.
GE HealthCare's (GEHC) New Solution to Aid Prostate Treatment
by Zacks Equity Research
GE HealthCare's (GEHC) MIM Software introduced the MIM Symphony HDR Prostate to provide direct tumor visualization using MRI images during live ultrasound procedures for HDR prostate treatments.
Here's Why You Should Retain Nevro (NVRO) Stock for Now
by Zacks Equity Research
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
Microbot Medical (MBOT) Progresses in Its Human Clinical Trial
by Zacks Equity Research
Microbot Medical's (MBOT) latest patient enrollment in its pivotal human clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY system.
3 Reasons Why You Should Hold Avantor (AVTR) Stock for Now
by Zacks Equity Research
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
Masimo (MASI) Preliminary Q2 Results Aided by Healthcare Unit
by Zacks Equity Research
Masimo's (MASI) second-quarter 2024 results are likely to reflect the strength in the Healthcare business.
EYE or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EYE vs. SYK: Which Stock Is the Better Value Option?
Stryker (SYK) Gains 11.6% YTD: What's Driving the Stock?
by Zacks Equity Research
Styker's (SYK) flagship Mako Total Knee Platform and a diversified product portfolio raise optimism about the stock.
Three Reasons to Hold BD (BDX) Stock in Your Portfolio Now
by Zacks Equity Research
BD's (BDX) robust product portfolio raises optimism about the stock.
Merit Medical (MMSI) Inks Deal to Boost Endoscopy Portfolio
by Zacks Equity Research
Merit Medical's (MMSI) latest asset acquisition is likely to expand its endoscopy portfolio with a minimally-invasive solution for GERD patients, thereby improving patient outcomes.
Here's Why You Should Retain Ensign Group (ENSG) Stock Now
by Zacks Equity Research
Ensign Group (ENSG) remains well-poised for growth on the back of solid segmental contributions, an expanding healthcare portfolio and sound cash reserves.
Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform Mako and its broad product portfolio.
The Zacks Analyst Blog Highlights NIKE, Stryker and TJX
by Zacks Equity Research
NIKE, Stryker and TJX are included in this Analyst Blog.
Top Analyst Reports for NIKE, Stryker & TJX
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including NIKE, Inc. (NKE), Stryker Corporation (SYK) and The TJX Companies, Inc. (TJX).
Why Is QuidelOrtho (QDEL) Down 2.4% Since Last Earnings Report?
by Zacks Equity Research
QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stryker's (SYK) LIFEPAK 35 to Offer Advanced Monitoring System
by Zacks Equity Research
Stryker (SYK) announces the launch of LIFEPAK 35 monitor/defibrillator, which is likely to aid emergency responders to reduce cognitive load during demanding situations by improving workflow.
Stryker's (SYK) Acquisition of Artelon Set to Expand Its Market
by Zacks Equity Research
Stryker (SYK) announces the signing of the definitive agreement to acquire a privately held company, Artelon, to strengthen its foothold in the soft tissue fixation market.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Why Is SurModics (SRDX) Up 21.9% Since Last Earnings Report?
by Zacks Equity Research
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stryker (SYK) to Launch Gamma4 Hip Fracture System in Europe
by Zacks Equity Research
Stryker (SYK) announces plan to launch its Gamma4 Hip Fracture Nailing System in Europe. It completes initial surgeries successfully.
Stryker (SYK) Issues Safety Notice for Its Total Knee System
by Zacks Equity Research
Stryker (SYK) issues urgent field safety notice for the Mako Total Knee systems, the application software of which generated software error codes. The company also shares risk mitigation steps.
Stryker's (SYK) Q1 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings reflect strong performance across its segments and geographies. Operating and gross margins increase, with earnings and revenues beating their respective estimates.
Here's What Key Metrics Tell Us About Stryker (SYK) Q1 Earnings
by Zacks Equity Research
The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Stryker (SYK) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 6.38% and 3.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?